Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Sep 4 2009

Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Thomas Weisel Partners 2009 Healthcare Conference in Boston.

Mr. Jackson will provide a corporate overview and an update on the company's progress with two ongoing Phase 2 clinical trials of CPX-351 in newly diagnosed acute myeloid leukemia (AML) patients and first-relapse AML patients. The presentation will be given on Thursday, September 10, 2009 at 1:30pm EDT in the Blaxton Room of the Four Seasons Hotel.

Source:

http://www.celatorpharma.com

Posted in: Drug Trial News

Tags: , , , , , , , , , ,

Comments (0)

Suggested Reading

MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals
Study highlights growing burden of neurological disorders worldwide
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
Common HIV drugs linked to reduced Alzheimer's disease risk
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Lancet Commission predicts sharp increase in global prostate cancer cases
LabVantage celebrates customer success with record number of software deployments in FY 2024
Study highlights global fertility decline and its implications for the future

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
SickKids study offers new path for pediatric rare disease clinical trials